Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

The purpose of this registry is to acquire safety data (including assessment of anti-rHuPH20 antibodies), regarding the course and outcome of pregnancy in women ever treated with HYQVIA. Development of the fetus/infant at birth and for the first 2 years will also be followed.

Inclusion Criteria:

• For the expectant mother only: Participant became pregnant during or after treatment with HYQVIA
• Participant/Participant's legally authorized representative is willing to sign an informed consent form (ICF)

Exclusion Criteria:

• There are no applicable Exclusion Criteria